Wilmington, DE -- (SBWIRE) -- 09/27/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Novavax, Inc. (NASDAQ:NVAX) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).
Novavax, Inc. (NASDAQ:NVAX) a clinical-stage biopharmaceutical company that focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases is currently down (-0.78%) on 2,512,997 shares traded after Novavax Completed $100 Million Public Offering of Common Stock. Novavax, Inc. (NASDAQ:NVAX) is currently down (-10.86%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Novavax, Inc. (NASDAQ:NVAX)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a biopharmaceutical company that focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders is currently up (+3.09%) on 2,347,821 shares traded after Mills Roger who is EVP, DEVELOPMENT AND CMO at ACADIA Pharmaceuticals, Inc., sold 35,965 shares at $25.01 per share for a total value of $899,312. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is currently up (+1438.89%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)